At a glance
- Originator Novartis
- Class Analgesics; Antidepressants; Anxiolytics
- Mechanism of Action Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder
Most Recent Events
- 28 Sep 2000 No-Development-Reported for Anxiety disorders in Switzerland (Unknown route)
- 28 Sep 2000 No-Development-Reported for Depression in Switzerland (Unknown route)
- 17 Jun 1997 Phase-II clinical trials for Anxiety disorders in Switzerland (Unknown route)